KYORIN Pharmaceutical Co., Ltd.

PickUp

These websites are only available in Japanese.

News Releases

August 3, 2026: KYORIN to Commence Promotion Activities for Allergic Conjunctivitis Treatment Alesion® Eyelid Cream 0.5%
July 30, 2026: Consolidated Financial Results for the Three Months Ended June 30, 2026[Under Japanese GAAP]
July 30, 2026: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2027
July 13, 2026: Santen and KYORIN announce joint marketing agreement in Japan for allergic conjunctivitis treatment Alesion® Eyelid Cream 0.5%
June 11, 2026: Notice Regarding the Initiation of a Confirmatory Study for "KRP-DC125," a Digital Therapeutic (DTx) for Chronic Cough

About Kyorin

KYORIN Holdings, Inc. has merged its wholly owned subsidiary KYORIN Pharmaceutical. Co., Ltd and has changed its trade name to “KYORIN Pharmaceutical. Co., Ltd.” on April 2023.

More detail

Investor Relations

This section provides information on the long-term vision, medium-term business plan, financial and performance results, IR library and stock.

More detail

Sustainability

Following our corperate philosophy, Kyorin Group is working to contribute to society’s continuous development and our sustainable growth by fulfilling our social responsibility through we business activities with new drug as our core business.

More detail

R&D

A large number of unmet medical needs are still present in the world. This section provides information on our initiatives for drug discovery, and development pipeline.

More detail

PickUp

News Releases

Contens

About Kyorin

Investor Relations

Sustainability

R&D

Kyorin Group